BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37079068)

  • 1. Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort.
    Cattaneo D; Bucelli C; Marchetti A; Lionetti M; Fermo E; Bellani V; De Magistris C; Maeda A; Marella A; Primignani M; Consonni D; Gianelli U; Neri A; Baldini L; Bolli N; Iurlo A
    Ann Hematol; 2023 Jun; 102(6):1409-1420. PubMed ID: 37079068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis.
    Magaz M; Alvarez-Larrán A; Colomer D; López-Guerra M; García-Criado MÁ; Mezzano G; Belmonte E; Olivas P; Soy G; Cervantes F; Darnell A; Ferrusquía-Acosta J; Baiges A; Turon F; Hernández-Gea V; García-Pagán JC
    J Hepatol; 2021 Jan; 74(1):89-95. PubMed ID: 32679300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular landscape of myeloproliferative neoplasms associated with splanchnic vein thrombosis: Current perspective.
    Pescia C; Lopez G; Cattaneo D; Bucelli C; Gianelli U; Iurlo A
    Leuk Res; 2024 Jan; 136():107420. PubMed ID: 38016412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study.
    Poisson J; Plessier A; Kiladjian JJ; Turon F; Cassinat B; Andreoli A; De Raucourt E; Goria O; Zekrini K; Bureau C; Lorre F; Cervantes F; Colomer D; Durand F; Garcia-Pagan JC; Casadevall N; Valla DC; Rautou PE; Marzac C;
    J Hepatol; 2017 Sep; 67(3):501-507. PubMed ID: 28483676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation Profile in BCR-ABL1-Negative Myeloproliferative Neoplasms: A Single-Center Experience From India.
    Maddali M; Kulkarni UP; Ravindra N; Arunachalam AK; Venkatraman A; Lionel S; Manipadam MT; Devasia AJ; Korula A; Fouzia NA; Abraham A; Srivastava A; George B; Balasubramanian P; Mathews V
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):13-20. PubMed ID: 33789164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
    Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
    Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
    De Stefano V; Qi X; Betti S; Rossi E
    Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
    Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
    J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.
    Rabade N; Subramanian PG; Kodgule R; Raval G; Joshi S; Chaudhary S; Mascarenhas R; Tembhare P; Gujral S; Patkar N
    Indian J Pathol Microbiol; 2018; 61(2):209-213. PubMed ID: 29676359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
    Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
    Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology.
    Garrote M; López-Guerra M; García-Pagán JC; Arellano-Rodrigo E; Ferrer-Marín F; Hernández-Boluda JC; Bellosillo B; Nomdedeu M; Hernández-Gea V; Triguero A; Guijarro F; Álamo J; Baiges A; Turon F; Colomer D; Cervantes F; Alvarez-Larrán A
    Ann Hematol; 2024 Mar; 103(3):737-747. PubMed ID: 38263537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis.
    Li M; De Stefano V; Song T; Zhou X; Guo Z; Zhu J; Qi X
    Thromb Res; 2018 Jul; 167():96-103. PubMed ID: 29803161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis.
    Turon F; Cervantes F; Colomer D; Baiges A; Hernández-Gea V; Garcia-Pagán JC
    J Hepatol; 2015 Jan; 62(1):72-4. PubMed ID: 25173966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Visceral Vein Thrombosis of Myeloproliferative Neoplasm --Review].
    Zhang X; Yang J; Hao HL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1627-1630. PubMed ID: 36208278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biomarkers of thrombosis in myeloproliferative neoplasms.
    Barbui T; Falanga A
    Thromb Res; 2016 Apr; 140 Suppl 1():S71-5. PubMed ID: 27067982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
    Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
    Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms].
    Han X; Bai BB; Feng CC; Zhao S; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):190-196. PubMed ID: 38387920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms.
    Hinze A; Rinke J; Crodel CC; Möbius S; Schäfer V; Heidel FH; Hochhaus A; Ernst T
    Br J Haematol; 2023 Jul; 202(2):308-317. PubMed ID: 37139709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.